HBM1047 / Harbour BioMed - LARVOL DELTA

Harbour BioMed Reports Full Year 2022 Financial Results (PRNewswire) - "In addition, HBM7022 (CLDN18.2xCD3), HBM7004 (B7H4x4-1BB), HBM9027 (PD-L1xCD40), HBM9033 (MSLN ADC), HBM1047 (CD200R1) and HBM9014 (LIFR) are all preclinical stage products in the company's pipeline. With the efficient output of the technology platforms as well as the rich expertise of our R&D team, the Company aims to file at least one IND each year moving forward."

IND • Oncology • Solid Tumor

HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model (SITC 2022) - "In addition, HBM1047 had a favorable PK profile in mice and exhibited good developability properties. Conclusions In conclusion, HBM1047 represents a novel fully human anti-CD200R1 antagonistic antibody with promising therapeutic potential for the treatment of cancer."

IO biomarker • Preclinical • Brain Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD200 • CD8

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting (PRNewswire) - "Harbour BioMed...announced today that the Company will present new preclinical data of five portfolio assets including HBM7008, HBM7004, HBM1047, HBM1020 and HBM1022 in five poster presentations at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, via in person/virtual attendance, November 8-12, 2022."

Preclinical • Oncology • Solid Tumor